Drugs / Lenti-HPV-07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06319963 | Aug 2024 → Jun 2026 overdue | cervical carcinoma, oropharynx squamous cell carcinoma | Theravectys S.A. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lenti-HPV-07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06319963 ↗ |
| Modality | Vaccine | “Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07)” NCT06319963 ↗ |
| Route | Intramuscular | “two Lenti-HPV-07 intramuscular injections one month apart” NCT06319963 ↗ |